Clinical Research Papers:
Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma
Metrics: PDF 3449 views | HTML 2003 views | ?
Zhiao Chen1,*, Xinyuan Lu2,*, Zhichao Wang3, Guangzhi Jin2, Qifeng Wang4, Di Chen5, Taoyang Chen6, Jinjun Li5, Jia Fan3, Wenming Cong2, Qiang Gao3 and Xianghuo He1
1 Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
2 Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
3 Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China
4 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
5 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Qi Dong Liver Cancer Institute, Qi Dong, Jiangsu, China
* These authors contributed equally to this work
Xianghuo He, email:
Qiang Gao, email:
Wenming Cong, email:
Keywords: Pyruvate kinase isoform M2, Tripartite motif-containing protein 35, Hepatocellular carcinoma, Prognosis; biomarker
Received: October 14, 2014 Accepted: December 10, 2014 Published: December 11, 2014
The identification of prognostic markers for hepatocellular carcinoma (HCC) is needed for clinical practice. Tripartite motif-containing 35 (TRIM35) is a tumor suppressor of HCC. TRIM35 inhibits phosphorylation of pyruvate kinase isoform M2 (PKM2), which is involved in aerobic glycolysis of cancer cells. We found that expression of PKM2 was significantly increased in HCC tissues. This overexpression of PKM2 was correlated with a high TNM stage and level of vascular invasion. Patients with HCC who were positive for PKM2 expression and negative for TRIM35 expression had shorter overall survival and time to recurrence than patients who were negative for PKM2 and positive for TRIM35. Furthermore, PKM2/TRIM35 combination was an independent and significant risk factor for recurrence and survival. In conclusion, PKM2 (+) and TRIM35 (-) contribute to the aggressiveness and poor prognosis of HCC. PKM2/TRIM35 expression could be a biomarker for the prognosis of HCC and target for cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.